Amedisys (AMED) Stock Forecast & Price Target

Amedisys Inc. demonstrated a solid performance in its financial results for 4Q24, with total visits increasing by 5.2% year-over-year and consolidating revenues reaching $598.1 million, reflecting a growth of 4.8% year-over-year. The Hospice segment saw net revenue per day rise by 2.8% to $179.02, highlighting the company's ability to drive revenue from its services. Furthermore, the High Acuity Care segment showed remarkable growth, with revenues up 37.3% year-over-year, indicating a significant expansion in this area despite slight underperformance compared to estimates.

Amedisys Inc experienced a decline in Medicare revenues by -3.9% year-over-year, alongside a decrease in adjusted EBITDA for its Home Health segment, which reported a 5.0% revenue increase yet faced a -5.0% decline in adjusted EBITDA, contributing to a lower EBITDA margin of 15.1%. The company's Hospice segment also showed underperformance, with a revenue increase of 3.3% but an adjusted EBITDA rise of only 1.6%, resulting in a margin contraction to 24.3%. Consolidated adjusted EBITDA fell short by -7.5% compared to projections, reflecting weaknesses across core segments and a concerning trend in hospice admissions and patient growth metrics.